Bio-Techne Corporation (TECH)
USD 48.81
(-6.69%)
USD 48.81
(-6.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 563.03 Million USD | 19.57% |
| 2023 | 470.87 Million USD | 2.38% |
| 2022 | 459.9 Million USD | 16.27% |
| 2021 | 395.55 Million USD | 21.42% |
| 2020 | 325.77 Million USD | -0.31% |
| 2019 | 326.77 Million USD | 10.41% |
| 2018 | 295.96 Million USD | 17.09% |
| 2017 | 252.75 Million USD | 35.84% |
| 2016 | 186.06 Million USD | 16.11% |
| 2015 | 160.25 Million USD | 74.83% |
| 2014 | 91.66 Million USD | 22.49% |
| 2013 | 74.83 Million USD | 4.34% |
| 2012 | 71.72 Million USD | 15.9% |
| 2011 | 61.88 Million USD | 6.22% |
| 2010 | 58.25 Million USD | 0.98% |
| 2009 | 57.68 Million USD | -4.24% |
| 2008 | 60.24 Million USD | 14.4% |
| 2007 | 52.66 Million USD | 8.81% |
| 2006 | 48.39 Million USD | 9.8% |
| 2005 | 44.07 Million USD | -0.05% |
| 2004 | 44.09 Million USD | 5.25% |
| 2003 | 41.89 Million USD | -8.07% |
| 2002 | 45.57 Million USD | 10.82% |
| 2001 | 41.12 Million USD | -0.09% |
| 2000 | 41.16 Million USD | 0.89% |
| 1999 | 40.8 Million USD | 44.17% |
| 1998 | 28.3 Million USD | -1.05% |
| 1997 | 28.6 Million USD | 13.04% |
| 1996 | 25.3 Million USD | 17.67% |
| 1995 | 21.5 Million USD | 22.86% |
| 1994 | 17.5 Million USD | 75.0% |
| 1993 | 10 Million USD | 16.28% |
| 1992 | 8.6 Million USD | 4.88% |
| 1991 | 8.2 Million USD | 18.84% |
| 1990 | 6.9 Million USD | 18.97% |
| 1989 | 5.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 138.58 Million USD | 7.16% |
| 2024 Q1 | 129.32 Million USD | 17.39% |
| 2024 Q3 | 133.26 Million USD | -3.84% |
| 2024 Q4 | 125.88 Million USD | -5.54% |
| 2024 FY | 520.02 Million USD | 10.44% |
| 2023 FY | 470.87 Million USD | 2.38% |
| 2023 Q1 | 123.27 Million USD | 2.92% |
| 2023 Q2 | 115.46 Million USD | -6.33% |
| 2023 Q4 | 110.17 Million USD | -9.66% |
| 2023 Q3 | 121.95 Million USD | 5.61% |
| 2022 Q3 | 111.01 Million USD | -8.51% |
| 2022 Q4 | 119.77 Million USD | 7.9% |
| 2022 FY | 459.9 Million USD | 16.27% |
| 2022 Q2 | 121.34 Million USD | 12.59% |
| 2022 Q1 | 107.77 Million USD | 0.38% |
| 2021 Q3 | 99.64 Million USD | -0.26% |
| 2021 Q4 | 107.36 Million USD | 7.74% |
| 2021 Q1 | 88.63 Million USD | 19.78% |
| 2021 Q2 | 99.9 Million USD | 12.71% |
| 2021 FY | 395.55 Million USD | 21.42% |
| 2020 Q4 | 74 Million USD | -10.05% |
| 2020 Q1 | 85.08 Million USD | 0.11% |
| 2020 Q2 | 84.41 Million USD | -0.79% |
| 2020 Q3 | 82.27 Million USD | -2.53% |
| 2020 FY | 325.77 Million USD | -0.31% |
| 2019 FY | 326.77 Million USD | 10.41% |
| 2019 Q1 | 81.84 Million USD | 3.25% |
| 2019 Q4 | 84.99 Million USD | 5.56% |
| 2019 Q3 | 80.52 Million USD | 1.39% |
| 2019 Q2 | 79.41 Million USD | -2.96% |
| 2018 Q1 | 71.83 Million USD | 17.97% |
| 2018 FY | 295.96 Million USD | 17.09% |
| 2018 Q4 | 79.26 Million USD | 18.0% |
| 2018 Q3 | 67.17 Million USD | -13.53% |
| 2018 Q2 | 77.68 Million USD | 8.14% |
| 2017 Q2 | 68.93 Million USD | 16.79% |
| 2017 Q3 | 61.87 Million USD | -10.24% |
| 2017 Q1 | 59.02 Million USD | 18.82% |
| 2017 FY | 252.75 Million USD | 35.84% |
| 2017 Q4 | 60.89 Million USD | -1.59% |
| 2016 Q1 | 44.36 Million USD | 7.45% |
| 2016 FY | 186.06 Million USD | 16.11% |
| 2016 Q2 | 45.56 Million USD | 2.71% |
| 2016 Q4 | 49.68 Million USD | 6.93% |
| 2016 Q3 | 46.46 Million USD | 1.98% |
| 2015 Q3 | 39.95 Million USD | -2.94% |
| 2015 FY | 160.25 Million USD | 74.83% |
| 2015 Q4 | 41.28 Million USD | 3.34% |
| 2015 Q2 | 41.16 Million USD | 8.75% |
| 2015 Q1 | 37.85 Million USD | 52.95% |
| 2014 Q1 | 21.72 Million USD | 1.07% |
| 2014 Q2 | 22.84 Million USD | 5.18% |
| 2014 FY | 91.66 Million USD | 22.49% |
| 2014 Q4 | 24.74 Million USD | 10.76% |
| 2014 Q3 | 22.34 Million USD | -2.22% |
| 2013 FY | 74.83 Million USD | 4.34% |
| 2013 Q4 | 21.49 Million USD | 24.95% |
| 2013 Q3 | 17.2 Million USD | -6.31% |
| 2013 Q2 | 18.35 Million USD | 3.26% |
| 2013 Q1 | 17.78 Million USD | -10.08% |
| 2012 Q1 | 17.44 Million USD | 4.42% |
| 2012 Q3 | 17.02 Million USD | -2.67% |
| 2012 Q2 | 17.48 Million USD | 0.28% |
| 2012 Q4 | 19.77 Million USD | 16.17% |
| 2012 FY | 71.72 Million USD | 15.9% |
| 2011 Q4 | 16.7 Million USD | 6.38% |
| 2011 FY | 61.88 Million USD | 6.22% |
| 2011 Q1 | 14.34 Million USD | 2.77% |
| 2011 Q2 | 15.13 Million USD | 5.56% |
| 2011 Q3 | 15.7 Million USD | 3.71% |
| 2010 Q1 | 14.43 Million USD | 4.59% |
| 2010 FY | 58.25 Million USD | 0.98% |
| 2010 Q4 | 13.95 Million USD | -1.94% |
| 2010 Q3 | 14.23 Million USD | -9.0% |
| 2010 Q2 | 15.63 Million USD | 8.36% |
| 2009 Q2 | 15.78 Million USD | 5.33% |
| 2009 Q3 | 13.11 Million USD | -16.97% |
| 2009 Q4 | 13.79 Million USD | 5.26% |
| 2009 FY | 57.68 Million USD | -4.24% |
| 2009 Q1 | 14.99 Million USD | -0.6% |
| 2008 FY | 60.24 Million USD | 14.4% |
| 2008 Q3 | 15.11 Million USD | -8.33% |
| 2008 Q1 | 13.55 Million USD | 2.28% |
| 2008 Q2 | 16.48 Million USD | 21.61% |
| 2008 Q4 | 15.08 Million USD | -0.24% |
| 2007 Q4 | 13.25 Million USD | 3.56% |
| 2007 FY | 52.66 Million USD | 8.81% |
| 2007 Q3 | 12.8 Million USD | -10.34% |
| 2007 Q2 | 14.27 Million USD | 15.85% |
| 2007 Q1 | 12.32 Million USD | 6.87% |
| 2006 Q2 | 13.04 Million USD | 11.86% |
| 2006 Q1 | 11.66 Million USD | 6.81% |
| 2006 FY | 48.39 Million USD | 9.8% |
| 2006 Q4 | 11.53 Million USD | -5.11% |
| 2006 Q3 | 12.15 Million USD | -6.84% |
| 2005 Q1 | 10.62 Million USD | -6.33% |
| 2005 FY | 44.07 Million USD | -0.05% |
| 2005 Q2 | 11.21 Million USD | 5.53% |
| 2005 Q4 | 10.91 Million USD | -3.5% |
| 2005 Q3 | 11.31 Million USD | 0.89% |
| 2004 Q1 | 10.44 Million USD | -3.17% |
| 2004 Q3 | 10.93 Million USD | -3.78% |
| 2004 Q4 | 11.34 Million USD | 3.72% |
| 2004 Q2 | 11.36 Million USD | 8.83% |
| 2004 FY | 44.09 Million USD | 5.25% |
| 2003 Q4 | 10.78 Million USD | 2.97% |
| 2003 Q3 | 10.47 Million USD | 1.07% |
| 2003 FY | 41.89 Million USD | -8.07% |
| 2003 Q1 | 10.41 Million USD | -16.81% |
| 2003 Q2 | 10.36 Million USD | -0.51% |
| 2002 FY | 45.57 Million USD | 10.82% |
| 2002 Q1 | 10.66 Million USD | 849.11% |
| 2002 Q2 | 11.28 Million USD | 5.79% |
| 2002 Q3 | 11.1 Million USD | -1.55% |
| 2002 Q4 | 12.52 Million USD | 12.77% |
| 2001 FY | 41.12 Million USD | -0.09% |
| 2001 Q4 | 1.12 Million USD | -91.85% |
| 2001 Q3 | 13.79 Million USD | 26.49% |
| 2001 Q2 | 10.9 Million USD | 0.36% |
| 2001 Q1 | 10.86 Million USD | 7.89% |
| 2000 Q3 | 9.13 Million USD | -12.19% |
| 2000 Q1 | 10.7 Million USD | 5.94% |
| 2000 Q2 | 10.4 Million USD | -2.8% |
| 2000 FY | 41.16 Million USD | 0.89% |
| 2000 Q4 | 10.06 Million USD | 10.27% |
| 1999 Q4 | 10.1 Million USD | -0.98% |
| 1999 Q3 | 10.2 Million USD | -1.92% |
| 1999 FY | 40.8 Million USD | 44.17% |
| 1999 Q2 | 10.4 Million USD | 2.97% |
| 1999 Q1 | 10.1 Million USD | 38.36% |
| 1998 Q4 | 7.3 Million USD | 4.29% |
| 1998 Q3 | 7 Million USD | 1.45% |
| 1998 Q2 | 6.9 Million USD | -2.82% |
| 1998 Q1 | 7.1 Million USD | 1.43% |
| 1998 FY | 28.3 Million USD | -1.05% |
| 1997 Q1 | 6.7 Million USD | 0.0% |
| 1997 FY | 28.6 Million USD | 13.04% |
| 1997 Q2 | 7.2 Million USD | 7.46% |
| 1997 Q3 | 7.6 Million USD | 5.56% |
| 1997 Q4 | 7 Million USD | -7.89% |
| 1996 FY | 25.3 Million USD | 17.67% |
| 1996 Q4 | 6.7 Million USD | 1.52% |
| 1996 Q3 | 6.6 Million USD | 8.2% |
| 1996 Q1 | 6 Million USD | 1.69% |
| 1996 Q2 | 6.1 Million USD | 1.67% |
| 1995 Q1 | 4.8 Million USD | 6.67% |
| 1995 Q2 | 5.4 Million USD | 12.5% |
| 1995 Q3 | 5.4 Million USD | 0.0% |
| 1995 Q4 | 5.9 Million USD | 9.26% |
| 1995 FY | 21.5 Million USD | 22.86% |
| 1994 Q1 | 3.9 Million USD | 50.0% |
| 1994 FY | 17.5 Million USD | 75.0% |
| 1994 Q3 | 4.8 Million USD | 11.63% |
| 1994 Q4 | 4.5 Million USD | -6.25% |
| 1994 Q2 | 4.3 Million USD | 10.26% |
| 1993 FY | 10 Million USD | 16.28% |
| 1993 Q1 | 2.2 Million USD | 0.0% |
| 1993 Q2 | 2.5 Million USD | 13.64% |
| 1993 Q3 | 2.6 Million USD | 4.0% |
| 1993 Q4 | 2.6 Million USD | 0.0% |
| 1992 Q4 | 2.2 Million USD | 0.0% |
| 1992 Q3 | 2.2 Million USD | 15.79% |
| 1992 Q2 | 1.9 Million USD | -20.83% |
| 1992 FY | 8.6 Million USD | 4.88% |
| 1992 Q1 | 2.4 Million USD | 14.29% |
| 1991 Q2 | 2.1 Million USD | 23.53% |
| 1991 Q4 | 2.1 Million USD | -8.7% |
| 1991 Q1 | 1.7 Million USD | -5.56% |
| 1991 Q3 | 2.3 Million USD | 9.52% |
| 1991 FY | 8.2 Million USD | 18.84% |
| 1990 FY | 6.9 Million USD | 18.97% |
| 1990 Q4 | 1.8 Million USD | 5.88% |
| 1990 Q2 | 1.7 Million USD | 6.25% |
| 1990 Q3 | 1.7 Million USD | 0.0% |
| 1990 Q1 | 1.6 Million USD | 0.0% |
| 1989 FY | 5.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | 201.11 Million USD | -179.959% |
| Jaguar Health, Inc. | 42.01 Million USD | -1240.09% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -232.614% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -891.982% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 68.721% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -567.717% |
| ContextLogic Inc. | 387 Million USD | -45.488% |
| MiMedx Group, Inc. | 229.72 Million USD | -145.09% |
| MEI Pharma, Inc. | 34.78 Million USD | -1518.626% |
| AlloVir, Inc. | 180.93 Million USD | -211.186% |
| Novavax, Inc. | 779.12 Million USD | 27.734% |
| Aptorum Group Limited | 10.56 Thousand USD | -5328680.996% |
| Ardelyx, Inc. | 169.93 Million USD | -231.322% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -26.316% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -20362.352% |
| Vaxcyte, Inc. | 468.04 Million USD | -20.297% |
| Precigen, Inc. | 84.18 Million USD | -568.843% |
| Pharming Group N.V. | 225.49 Million USD | -149.695% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -235.488% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -675.899% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -332.232% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -129.664% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2799.496% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -2216.403% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -2216.403% |
| Bicycle Therapeutics plc | 216.92 Million USD | -159.558% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -146.213% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1724.554% |
| Acelyrin, Inc. | 422.06 Million USD | -33.401% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1386.807% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1419.099% |
| Senti Biosciences, Inc. | 94.7 Million USD | -494.519% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -355.706% |
| AbCellera Biologics Inc. | 275.23 Million USD | -104.569% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1810.615% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -227.535% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -325.98% |
| Chimerix, Inc. | 93.38 Million USD | -502.896% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1551.867% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -3125.291% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3947.833% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1010.684% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1138.946% |
| Alkermes plc | 996.24 Million USD | 43.484% |
| Fortress Biotech, Inc. | 200.19 Million USD | -181.245% |
| Fortress Biotech, Inc. | 200.19 Million USD | -181.245% |
| Agenus Inc. | 78.18 Million USD | -620.155% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1619.413% |
| Dyadic International, Inc. | 9.15 Million USD | -6051.619% |
| ImmuCell Corporation | 9.61 Million USD | -5754.402% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -2430.171% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -256.774% |
| Lantern Pharma Inc. | 17.87 Million USD | -3049.416% |
| Immix Biopharma, Inc. | 16.14 Million USD | -3388.229% |
| Incyte Corporation | 1.19 Billion USD | 52.705% |
| IO Biotech, Inc. | 91.44 Million USD | -515.727% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -594.578% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -8263.691% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -959.811% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1729.772% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -6562.395% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -564.619% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -47.975% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -39.517% |
| NextCure, Inc. | 67.63 Million USD | -732.442% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1801.773% |
| Onconetix, Inc. | 34.9 Million USD | -1512.949% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -4317.378% |
| Opthea Limited | 191.96 Million USD | -193.299% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1208.017% |
| PureTech Health plc | 144.59 Million USD | -289.385% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -584.996% |
| Seer, Inc. | 110.49 Million USD | -409.584% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -4366574.422% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1621.042% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -14182.906% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1796.904% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -210.555% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -234.275% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -252.368% |
| ChromaDex Corporation | 56.37 Million USD | -898.668% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2874.478% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -274.023% |
| CRISPR Therapeutics AG | 463.49 Million USD | -21.477% |
| Precision BioSciences, Inc. | 92.46 Million USD | -508.934% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -121.631% |
| Innoviva, Inc. | 132.15 Million USD | -326.048% |
| Summit Therapeutics Inc. | 87.68 Million USD | -542.108% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -697.573% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -502.322% |
| ESSA Pharma Inc. | 32.13 Million USD | -1652.154% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1333.206% |
| GT Biopharma, Inc. | 13.57 Million USD | -4047.311% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -156.125% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -117.033% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -941.122% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -5565.719% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -116.838% |
| Aptose Biosciences Inc. | 52.35 Million USD | -975.405% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -3807.178% |
| Soligenix, Inc. | 7.79 Million USD | -7122.846% |
| Century Therapeutics, Inc. | 56.07 Million USD | -904.154% |
| Kura Oncology, Inc. | 165.8 Million USD | -239.581% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -391.707% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -6668.109% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -22588.191% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -422.794% |
| Autolus Therapeutics plc | 196.72 Million USD | -186.205% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -565.083% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -383.49% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2804.808% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -74.988% |
| GRI Bio, Inc. | 11.33 Million USD | -4869.453% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -7879.916% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -329.168% |
| IGM Biosciences, Inc. | 265.59 Million USD | -111.995% |
| INmune Bio, Inc. | 29.89 Million USD | -1783.326% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -226.297% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1296.623% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -3423.539% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -3476.769% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -806.694% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -423.65% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -104.227% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -86.776% |
| Verastem, Inc. | 92.08 Million USD | -511.441% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -3038.631% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -203.157% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -363.762% |
| Histogen Inc. | 14.27 Million USD | -3845.06% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -3408.437% |
| Surrozen, Inc. | 18.55 Million USD | -2935.251% |
| Organovo Holdings, Inc. | 14.91 Million USD | -3674.985% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -10961.157% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -843.538% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -2095.341% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1097.802% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -7276.531% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -216.073% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1062.152% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -129.808% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -3564.05% |
| Apollomics, Inc. | 54.14 Million USD | -939.969% |
| Amarin Corporation plc | 272.35 Million USD | -106.728% |
| Mesoblast Limited | 5.9 Million USD | -9439.8% |
| Turnstone Biologics Corp. | 78.33 Million USD | -618.73% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -130.638% |
| Synaptogenix, Inc. | 8.31 Million USD | -6672.298% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -3760.133% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -122.496% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1589.282% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -6275.541% |
| Exelixis, Inc. | 1.58 Billion USD | 64.517% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1371.536% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -142.637% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 34.163% |
| NLS Pharmaceutics AG | 11.8 Million USD | -4668.663% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -6901.313% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1777.235% |
| Gritstone bio, Inc. | 148.37 Million USD | -279.473% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -717.646% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -3341.513% |
| Avid Bioservices, Inc. | 25.99 Million USD | -2065.868% |
| Insmed Incorporated | 949.26 Million USD | 40.687% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -3488.57% |
| MediWound Ltd. | 18.86 Million USD | -2884.095% |
| OmniAb, Inc. | 83.89 Million USD | -571.123% |
| Alector, Inc. | 248.8 Million USD | -126.3% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -140.299% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -977.566% |
| Zai Lab Limited | 547.47 Million USD | -2.843% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -41.235% |
| Aura Biosciences, Inc. | 84.99 Million USD | -562.469% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -127.824% |
| Immunic, Inc. | 99.22 Million USD | -467.448% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -254.086% |
| Veracyte, Inc. | 357.93 Million USD | -57.303% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 93.755% |
| FibroGen, Inc. | 398.11 Million USD | -41.427% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3862.273% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -8074.264% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -7801.49% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 82.706% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -2076.164% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -77.871% |
| TG Therapeutics, Inc. | 198.47 Million USD | -183.683% |
| Galecto, Inc. | 35.62 Million USD | -1480.372% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -1283.762% |
| Fortrea Holdings Inc. | 457.3 Million USD | -23.122% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -937.325% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1849.716% |
| XBiotech Inc. | 37.51 Million USD | -1401.037% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -717.646% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -2626.713% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -296.336% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -468.296% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -408.543% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 41.243% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1851.947% |
| Vaxxinity, Inc. | 56.05 Million USD | -904.512% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -30.745% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -2423.898% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -407.851% |
| NexImmune, Inc. | 28.16 Million USD | -1898.895% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -10079.792% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -3046.786% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 80.001% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -2111.552% |
| Scopus BioPharma Inc. | 11.71 Million USD | -4706.188% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -343.121% |
| Ainos, Inc. | 12.95 Million USD | -4246.898% |
| Pluri Inc. | 22.48 Million USD | -2404.622% |
| Prothena Corporation plc | 282.4 Million USD | -99.372% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -181.489% |
| Celularity Inc. | 215.05 Million USD | -161.808% |
| Rallybio Corporation | 78.93 Million USD | -613.322% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2781.174% |
| MeiraGTx Holdings plc | 151.07 Million USD | -272.681% |
| Omeros Corporation | 94.75 Million USD | -494.23% |
| Humacyte, Inc. | 23.49 Million USD | -2296.217% |
| Immunocore Holdings plc | 308.04 Million USD | -82.781% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -16508.82% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -548.177% |
| Blueprint Medicines Corporation | 722.86 Million USD | 22.11% |
| CalciMedica, Inc. | 21.81 Million USD | -2480.735% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -654.137% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -250.716% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -228.696% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -90.9% |
| Pulmatrix, Inc. | 22.03 Million USD | -2454.855% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1528.457% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -533.582% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -2.08% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -676.06% |
| Cytokinetics, Incorporated | 173.61 Million USD | -224.309% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1535.838% |
| Nutriband Inc. | 5.73 Million USD | -9719.253% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1190.989% |
| Vor Biopharma Inc. | 126.03 Million USD | -346.729% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 52.653% |
| Evogene Ltd. | 27.79 Million USD | -1926.049% |
| ProKidney Corp. | 151.52 Million USD | -271.589% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -659.068% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -7219.57% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 8.334% |
| CorMedix Inc. | 48.95 Million USD | -1050.05% |
| BioLineRx Ltd. | 50.8 Million USD | -1008.301% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -273.616% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1378.879% |
| Atai Life Sciences N.V. | 125.78 Million USD | -347.62% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -589.667% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -591.618% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -122.94% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1619.728% |
| MediciNova, Inc. | 10.9 Million USD | -5065.37% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -337.074% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -7655.867% |
| GeoVax Labs, Inc. | 6.02 Million USD | -9249.433% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -18.196% |
| Biomea Fusion, Inc. | 126.13 Million USD | -346.378% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 57.08% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1470.892% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -194.648% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -144.849% |
| Absci Corporation | 73.66 Million USD | -664.313% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1941.328% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -321.468% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -132.505% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -114.861% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -170.7% |
| Allakos Inc. | 196.05 Million USD | -187.183% |
| Imunon, Inc. | 20.31 Million USD | -2672.167% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -396.205% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -52.746% |
| BioAtla, Inc. | 129.68 Million USD | -334.152% |
| NLS Pharmaceutics AG | 11.8 Million USD | -4668.663% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -3453.866% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -563.038% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -1248.338% |
| XOMA Corporation | 46.46 Million USD | -1111.801% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -406.462% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -295.218% |
| aTyr Pharma, Inc. | 12.97 Million USD | -4238.077% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -443.18% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -225.701% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -121.004% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1405.13% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -6745.614% |
| Akari Therapeutics, Plc | 16.8 Million USD | -3250.226% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -24660.177% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -88.107% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -8267.686% |
| UroGen Pharma Ltd. | 138.88 Million USD | -305.391% |
| Sutro Biopharma, Inc. | 243 Million USD | -131.695% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -7639.77% |
| Orgenesis Inc. | 45.75 Million USD | -1130.498% |
| Entera Bio Ltd. | 8.86 Million USD | -6254.842% |
| GH Research PLC | 41.22 Million USD | -1265.87% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -2090.131% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -577.927% |
| Xencor, Inc. | 306.97 Million USD | -83.414% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -11312.322% |
| Replimune Group, Inc. | 234.77 Million USD | -139.823% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -2647.887% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -193.561% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -8267.686% |
| Portage Biotech Inc. | 18.19 Million USD | -2993.791% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -7655.867% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -436.427% |
| OncoCyte Corporation | 25.63 Million USD | -2096.197% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -9136.8% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -4814.341% |
| Purple Biotech Ltd. | -22.46 Million USD | 2606.071% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -3316.499% |
| scPharmaceuticals Inc. | 65.17 Million USD | -763.848% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -6561.027% |
| HilleVax, Inc. | 133.34 Million USD | -322.242% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -5374.37% |
| Tharimmune, Inc. | 9.45 Million USD | -5854.795% |
| Genprex, Inc. | 31.06 Million USD | -1712.713% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -200.246% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1694.432% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -73499.869% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -10236.834% |
| OKYO Pharma Limited | 8243.57 USD | -6829938.442% |
| Savara Inc. | 15.74 Million USD | -3475.986% |
| Curis, Inc. | 58.35 Million USD | -864.851% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1575.243% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -10956.266% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -7446.428% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1983.632% |
| BeiGene, Ltd. | 3.28 Billion USD | 82.869% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -2723.765% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -12.887% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -266.438% |
| Erasca, Inc. | 141.52 Million USD | -297.837% |
| bluebird bio, Inc. | 240.23 Million USD | -134.373% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -12337.425% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 67.758% |
| DBV Technologies S.A. | 92.16 Million USD | -510.936% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -12337.425% |
| Moderna, Inc. | 6.39 Billion USD | 91.194% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1221.409% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -3819.247% |
| Molecular Templates, Inc. | 63.09 Million USD | -792.424% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -744.124% |
| Travere Therapeutics, Inc. | 472 Million USD | -19.287% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -292.879% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -806.928% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1196.907% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -170.523% |
| MacroGenics, Inc. | 217.21 Million USD | -159.208% |
| RenovoRx, Inc. | 11.39 Million USD | -4840.672% |
| Adicet Bio, Inc. | 152.03 Million USD | -270.328% |
| Prime Medicine, Inc. | 186.63 Million USD | -201.673% |
| Aditxt, Inc. | 25.95 Million USD | -2069.643% |
| Adagene Inc. | 41.83 Million USD | -1245.974% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -7602.209% |
| Quantum-Si incorporated | 111.65 Million USD | -404.249% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -227.634% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -3762.313% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1471.769% |
| SciSparc Ltd. | 9.01 Million USD | -6148.352% |
| Vericel Corporation | 142.04 Million USD | -296.395% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -6404.111% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -2338.602% |
| Generation Bio Co. | 144.46 Million USD | -289.735% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -578.115% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -551.213% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -90.396% |
| Invivyd, Inc. | 205.75 Million USD | -173.645% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -680.276% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -5903.505% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -648.185% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -5373.306% |
| 2seventy bio, Inc. | 289.88 Million USD | -94.227% |
| ADMA Biologics, Inc. | 66.58 Million USD | -745.582% |
| Clene Inc. | 41.07 Million USD | -1270.825% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -4296.034% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -927.518% |
| GeoVax Labs, Inc. | 6.02 Million USD | -9249.433% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -59.932% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1432.829% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1569.352% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -442.939% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1627.696% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -230.659% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 26.661% |
| Evaxion Biotech A/S | 22.27 Million USD | -2428.24% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -315.392% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -139.711% |
| Trevena, Inc. | 38.41 Million USD | -1365.751% |
| Surrozen, Inc. | 18.55 Million USD | -2935.251% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -604.283% |
| Cingulate Inc. | 22.75 Million USD | -2373.897% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 7615.203% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1160.526% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -6738.026% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -448.996% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 25.335% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -807.045% |
| Clearmind Medicine Inc. | 8.74 Million USD | -6341.099% |
| Kronos Bio, Inc. | 128.11 Million USD | -339.469% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -569.71% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -19096.791% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -458.421% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1852.996% |
| ImmunityBio, Inc. | 362.87 Million USD | -55.162% |
| Korro Bio, Inc. | 84.53 Million USD | -566.05% |
| Kineta, Inc. | 21.15 Million USD | -2561.368% |
| BioVie Inc. | 31.95 Million USD | -1662.239% |
| Codexis, Inc. | 66.51 Million USD | -746.446% |
| Celularity Inc. | 215.05 Million USD | -161.808% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -148.45% |
| Celcuity Inc. | 66.23 Million USD | -750.123% |
| Virax Biolabs Group Limited | 6.54 Million USD | -8499.871% |
| Cibus, Inc. | 320.3 Million USD | -75.782% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1209.393% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1563.63% |
| IN8bio, Inc. | 30.33 Million USD | -1755.948% |
| Kodiak Sciences Inc. | 277.32 Million USD | -103.028% |
| Annexon, Inc. | 143.72 Million USD | -291.753% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -341.284% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -2357.72% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -87874.844% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 27.777% |
| Eyenovia, Inc. | 25.4 Million USD | -2116.127% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -301.268% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -10022.959% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -611.51% |
| Arcellx, Inc. | 200.19 Million USD | -181.24% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1126.664% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -160.171% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -5554.705% |
| Moolec Science SA | 52.75 Million USD | -967.36% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -820.931% |
| Geron Corporation | 70.44 Million USD | -699.306% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1109.796% |
| Royalty Pharma plc | 862.4 Million USD | 34.713% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -498.519% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -5936.097% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -2388.182% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -170.937% |
| Humacyte, Inc. | 23.49 Million USD | -2296.217% |
| Structure Therapeutics Inc. | 102.77 Million USD | -447.837% |
| 89bio, Inc. | 151.2 Million USD | -272.37% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -602.639% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -3772.345% |
| Genelux Corporation | 24.33 Million USD | -2213.7% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1559.756% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -225.703% |
| Notable Labs, Ltd. | 14.77 Million USD | -3712.045% |
| Liquidia Corporation | 87.98 Million USD | -539.933% |
| Mustang Bio, Inc. | 48.5 Million USD | -1060.881% |
| Immunovant, Inc. | 282.7 Million USD | -99.158% |
| Quantum-Si incorporated | 111.65 Million USD | -404.249% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -2397.512% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -2547.477% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -451.934% |
| Acasti Pharma Inc. | 11.3 Million USD | -4882.205% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -2356.422% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -3423.539% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1109.744% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -49525.324% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -3444.247% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1831.059% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -1260.523% |
| PepGen Inc. | 84.76 Million USD | -564.227% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1800.169% |
| United Therapeutics Corporation | 885.1 Million USD | 36.387% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -2359.008% |
| Solid Biosciences Inc. | 104.31 Million USD | -439.749% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1620.488% |
| Immuneering Corporation | 58.41 Million USD | -863.895% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -10961.157% |
| Silo Pharma, Inc. | 3.92 Million USD | -14256.442% |
| Belite Bio, Inc | 31.66 Million USD | -1677.943% |
| XOMA Corporation | 46.46 Million USD | -1111.801% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -733.514% |
| Bionomics Limited | 17.89 Billion USD | 96.853% |
| Apogee Therapeutics, Inc. | 93 Million USD | -505.399% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1678.024% |
| uniQure N.V. | 285.08 Million USD | -97.498% |
| Cassava Sciences, Inc. | 105.95 Million USD | -431.384% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -7602.209% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -189.917% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1633.655% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -6676.454% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1815.424% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -10022.959% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3862.273% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -6234.11% |
| Altimmune, Inc. | 30.55 Million USD | -1742.646% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -31.659% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1678.024% |
| Compugen Ltd. | 43.97 Million USD | -1180.478% |
| Peak Bio, Inc. | 1249.13 USD | -45074391.846% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -659.632% |
| Benitec Biopharma Inc. | 22.38 Million USD | -2415.588% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -131.523% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1872.599% |
| Zura Bio Limited | 62.63 Million USD | -798.878% |
| PolyPid Ltd. | 21.04 Million USD | -2575.405% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -3359.32% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1872.599% |
| Instil Bio, Inc. | 85.78 Million USD | -556.337% |
| argenx SE | 1.53 Billion USD | 63.285% |
| Immunome, Inc. | 122.82 Million USD | -358.426% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1061.552% |
| Verona Pharma plc | 67.15 Million USD | -738.464% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -2075.155% |
| Shattuck Labs, Inc. | 93.61 Million USD | -501.447% |
| CervoMed Inc. | 14.95 Million USD | -3664.192% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -696.344% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -6489.876% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1003.998% |
| Moolec Science SA | 52.75 Million USD | -967.36% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -3323.054% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -324.758% |
| AnaptysBio, Inc. | 181.56 Million USD | -210.098% |
| Design Therapeutics, Inc. | 78.19 Million USD | -620.091% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -546.866% |
| NeurAxis, Inc. | 8.82 Million USD | -6282.794% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -4373.89% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1356.198% |
| Achilles Therapeutics plc | 75.25 Million USD | -648.175% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -2075.155% |
| 180 Life Sciences Corp. | 13.47 Million USD | -4077.622% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -2024.48% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -19096.791% |
| Nutriband Inc. | 5.73 Million USD | -9719.253% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -408.25% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -911.696% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1006.624% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -751.812% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -940.293% |
| Palisade Bio, Inc. | 13.32 Million USD | -4127.02% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1139.928% |
| Beam Therapeutics Inc. | 554.19 Million USD | -1.596% |
| Neurogene Inc. | 55.58 Million USD | -912.97% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -126.585% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1062.607% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -482.193% |
| Sesen Bio, Inc. | 78.38 Million USD | -618.336% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -574.064% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -4373.216% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -24.844% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -540.618% |
| Athira Pharma, Inc. | 125.46 Million USD | -348.758% |
| Vaccinex, Inc. | 23.45 Million USD | -2300.507% |
| HCW Biologics Inc. | 21.02 Million USD | -2577.629% |
| XOMA Corporation | 46.46 Million USD | -1111.801% |
| Nektar Therapeutics | 190.9 Million USD | -194.935% |
| Arvinas, Inc. | 480 Million USD | -17.3% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -24660.177% |
| Merus N.V. | 200.49 Million USD | -180.826% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -444.762% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1526.34% |
| Rezolute, Inc. | 70.38 Million USD | -699.919% |
| Clene Inc. | 41.07 Million USD | -1270.825% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -3337.677% |
| BeyondSpring Inc. | 24.86 Million USD | -2164.384% |
| Synlogic, Inc. | 58.53 Million USD | -861.934% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -3046.876% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -12434.261% |
| Peak Bio, Inc. | 1249.13 USD | -45074391.846% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -831.474% |
| Krystal Biotech, Inc. | 160.42 Million USD | -250.965% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -108.047% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -61.775% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -26006.094% |
| MannKind Corporation | 125.59 Million USD | -348.29% |
| Ikena Oncology, Inc. | 84.57 Million USD | -565.712% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -5736.415% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -528.385% |
| Gossamer Bio, Inc. | 183.75 Million USD | -206.401% |
| CohBar, Inc. | 12.38 Million USD | -4444.927% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1010.005% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1941.328% |
| Legend Biotech Corporation | 583.14 Million USD | 3.448% |
| Mural Oncology plc | 192.07 Million USD | -193.141% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -738.517% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -3387.331% |
| Disc Medicine, Inc. | 91.12 Million USD | -517.875% |
| Champions Oncology, Inc. | 28.11 Million USD | -1902.985% |
| REGENXBIO Inc. | 321.15 Million USD | -75.316% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -10402.041% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -909.827% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1345.148% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -392.352% |
| Vaxart, Inc. | 90.72 Million USD | -520.593% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -6508.433% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1215.694% |
| Cellectis S.A. | 97.32 Million USD | -478.544% |
| Longeveron Inc. | 21.25 Million USD | -2549.595% |
| Repare Therapeutics Inc. | 167.35 Million USD | -236.43% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 58.625% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -644.318% |
| Revolution Medicines, Inc. | 498.76 Million USD | -12.887% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -8364.206% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1180.973% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -654.845% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -708.557% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -4990.769% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 88.209% |
| Denali Therapeutics Inc. | 527.23 Million USD | -6.792% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -6404.111% |
| Veru Inc. | 101.34 Million USD | -455.549% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -2305.43% |
| Cingulate Inc. | 22.75 Million USD | -2373.897% |
| Passage Bio, Inc. | 108.38 Million USD | -419.461% |
| Context Therapeutics Inc. | 25.07 Million USD | -2145.633% |
| Exicure, Inc. | 14.07 Million USD | -3899.993% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -173.235% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1200.291% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -6035.134% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -123.001% |
| Nuvalent, Inc. | 149.49 Million USD | -276.635% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -6879.619% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -443.212% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -2525.013% |
| OmniAb, Inc. | 83.89 Million USD | -571.123% |
| Anew Medical, Inc. | 1.3 Million USD | -43182.692% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1618.468% |
| Lipocine Inc. | 15.08 Million USD | -3633.646% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -721.799% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -639.362% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1296.623% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -390.268% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -2415.364% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 15.223% |
| Ocugen, Inc. | 71.56 Million USD | -686.73% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -499.833% |
| Q32 Bio Inc. | 92.68 Million USD | -507.509% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -2559.106% |
| Alumis Inc. Common Stock | 158.17 Million USD | -255.962% |
| Equillium, Inc. | 50.6 Million USD | -1012.593% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -802.219% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -3949.022% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2884.552% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1099.206% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -419.093% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -4443.302% |
| Dominari Holdings Inc. | 23.83 Million USD | -2262.236% |
| Edesa Biotech, Inc. | 9.22 Million USD | -6004.887% |
| vTv Therapeutics Inc. | 11.9 Million USD | -4628.639% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -37.728% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -109.498% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -325.651% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -3807.009% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -243.954% |
| Nkarta, Inc. | 131.65 Million USD | -327.679% |
| BioCardia, Inc. | 12.12 Million USD | -4545.153% |
| Iterum Therapeutics plc | 47.46 Million USD | -1086.144% |